Suppr超能文献

过氧化物酶体增殖物激活受体(PPARs)是癌症治疗的潜在药物靶点。

Peroxisome proliferator-activated receptors (PPARs) are potential drug targets for cancer therapy.

作者信息

Gou Qian, Gong Xin, Jin Jianhua, Shi Juanjuan, Hou Yongzhong

机构信息

Department of Oncology, Affiliated Wujin People's Hospital, Jiangsu University, Changzhou, 212017, PR China.

Institute of Life Sciences, Jiangsu University, Zhenjiang, 212013, PR China.

出版信息

Oncotarget. 2017 Jul 27;8(36):60704-60709. doi: 10.18632/oncotarget.19610. eCollection 2017 Sep 1.

Abstract

Peroxisome-proliferator-activated receptors (PPARs) are nuclear hormone receptors including PPARα, PPARδ and PPARγ, which play an important role in regulating cancer cell proliferation, survival, apoptosis, and tumor growth. Activation of PPARs by endogenous or synthetic compounds regulates tumor progression in various tissues. Although each PPAR isotype suppresses or promotes tumor development depending on the specific tissues or ligands, the mechanism is still unclear. In this review, we summarized the regulative mechanism of PPARs on cancer progression.

摘要

过氧化物酶体增殖物激活受体(PPARs)是核激素受体,包括PPARα、PPARδ和PPARγ,它们在调节癌细胞增殖、存活、凋亡和肿瘤生长中发挥重要作用。内源性或合成化合物激活PPARs可调节各种组织中的肿瘤进展。尽管每种PPAR亚型根据特定组织或配体抑制或促进肿瘤发展,但其机制仍不清楚。在本综述中,我们总结了PPARs对癌症进展的调节机制。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/63c9/5601172/9a8b1cf51056/oncotarget-08-60704-g001.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验